Impact of CYP2C19*17 on the Pharmacokinetics of Proguanil and Clopidogrel
NCT ID: NCT01456546
Last Updated: 2013-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
31 participants
INTERVENTIONAL
2011-10-31
2013-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Change in CYP3A Activity by Route of Administration Using Metabolic Markers in Healthy Male Volunteers
NCT03366974
Risk of CYP2C19 Phenoconversion in Healthy Volunteers With Rapid, Normal, and Intermediate Predicted Metabolizers' Status
NCT05264142
Effects of Genotype on CYP2C9 Drug Interactions
NCT01061112
Prediction of Drug Interactions With CYP2C9 Substrates
NCT00226538
A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects
NCT02623296
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Period A: proguanil
Proguanil pharmacokinetics
Proguanil
2x350 mg Malarone followed by 3 days of blood- and urine sampling
Period B: clopidogrel
Clopidogrel pharmacokinetics
Clopidogrel
2x300 mg Plavix followed by 7 hours days of blood sampling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Proguanil
2x350 mg Malarone followed by 3 days of blood- and urine sampling
Clopidogrel
2x300 mg Plavix followed by 7 hours days of blood sampling
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written consent
* Age 18-65
* CYP2C19\*1 and or CYP2C19\*17 genotype.
Exclusion Criteria
* Alcohol abuse
* Pregnancy
* Breastfeeding
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Southern Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rasmus Steen Pedersen
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Pharmacology, University of Southern Denmark
Odense, Fyn, Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AKF-380
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.